369 related articles for article (PubMed ID: 1776834)
1. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness.
Gasparini G; Pozza F; Meli S; Reitano M; Santini G; Bevilacqua P
Anticancer Res; 1991; 11(6):2015-21. PubMed ID: 1776834
[TBL] [Abstract][Full Text] [Related]
2. Relationship of the epidermal growth factor-receptor to the growth fraction (Ki-67 antibody) and the flow cytometric S-phase as cell kinetics parameters, in human mammary carcinomas.
Gasparini G; Reitano M; Bevilacqua P; Meli S; Pozza F; Santini G
Anticancer Res; 1991; 11(4):1597-603. PubMed ID: 1746917
[TBL] [Abstract][Full Text] [Related]
3. DNA ploidy, proliferation, and neu-oncogene protein overexpression in breast carcinoma.
Lee AK; Wiley B; Loda M; Bosari S; Dugan JM; Hamilton W; Heatley GJ; Cook L; Silverman ML
Mod Pathol; 1992 Jan; 5(1):61-7. PubMed ID: 1347424
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306
[TBL] [Abstract][Full Text] [Related]
5. Comparison between Ki-67 index and S-phase fraction on fine-needle aspiration samples from breast carcinoma.
Bozzetti C; Nizzoli R; Camisa R; Guazzi A; Ceci G; Cocconi G; Mazzini G; Naldi N
Cancer; 1997 Oct; 81(5):287-92. PubMed ID: 9349516
[TBL] [Abstract][Full Text] [Related]
6. Comparison of proliferation activity in breast carcinoma by flow cytometry analysis of S-phase and quantitative analysis of MIB-1.
Masood S; Bui MM; Lu L
Ann Clin Lab Sci; 1998; 28(6):315-23. PubMed ID: 9846198
[TBL] [Abstract][Full Text] [Related]
7. Correlations of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: nuclear grade, S-phase, proliferating cell nuclear antigen, p53, epidermal growth factor receptor, and c-erb-B-2.
Dabbs DJ
Mod Pathol; 1995 Aug; 8(6):637-42. PubMed ID: 8532697
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of morphological parameters and flow cytometric DNA analysis in carcinoma of the breast.
Visscher DW; Zarbo RJ; Greenawald KA; Crissman JD
Pathol Annu; 1990; 25 Pt 1():171-210. PubMed ID: 2153277
[TBL] [Abstract][Full Text] [Related]
9. Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases.
Caly M; Genin P; Ghuzlan A A; Elie C; Fréneaux P; Klijanienko J; Rosty C; Sigal-Zafrani B; Vincent-Salomon A; Douggaz A; Zidane M; Sastre-Garau X
Anticancer Res; 2004; 24(5B):3283-8. PubMed ID: 15510624
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric deoxyribonucleic acid and cell cycle analysis of breast carcinomas by flow cytometry. Clinicopathologic correlations.
Visscher DW; Zarbo RJ; Jacobsen G; Kambouris A; Talpos G; Sakr W; Crissman JD
Lab Invest; 1990 Mar; 62(3):370-8. PubMed ID: 1690316
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
[TBL] [Abstract][Full Text] [Related]
12. A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Ki-67, proliferating cell nuclear antigen, and flow cytometric S-phase fraction.
Nordström B; Strang P; Bergström R; Nilsson S; Tribukait B
Cancer; 1996 Nov; 78(9):1942-51. PubMed ID: 8909315
[TBL] [Abstract][Full Text] [Related]
13. Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer.
Siitonen SM; Kallioniemi OP; Isola JJ
Am J Pathol; 1993 Apr; 142(4):1081-9. PubMed ID: 7682759
[TBL] [Abstract][Full Text] [Related]
14. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer.
Baak JP; Chin D; van Diest PJ; Ortiz R; Matze-Cok P; Bacus SS
Lab Invest; 1991 Feb; 64(2):215-23. PubMed ID: 1671789
[TBL] [Abstract][Full Text] [Related]
15. Comparison of quantitative and semiquantitative methods of assessing MIB-1 with the S-phase fraction in breast carcinoma.
MacGrogan G; Jollet I; Huet S; Sierankowski G; Picot V; Bonichon F; Coindre JM
Mod Pathol; 1997 Aug; 10(8):769-76. PubMed ID: 9267818
[TBL] [Abstract][Full Text] [Related]
16. [DNA content analysis of breast cancer cells recognized by monoclonal antibody].
Zhu LW
Zhonghua Zhong Liu Za Zhi; 1993 Sep; 15(5):347-50. PubMed ID: 8174478
[TBL] [Abstract][Full Text] [Related]
17. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
[TBL] [Abstract][Full Text] [Related]
18. Proliferation measurement in breast cancer by two different methods.
Martínez-Arribas F; Martín-Garabato E; Lafuente P; Tejerina A; Lucas R; Sánchez J; Schneider J
Anticancer Res; 2006; 26(1A):199-202. PubMed ID: 16475699
[TBL] [Abstract][Full Text] [Related]
19. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up.
Thor AD; Schwartz LH; Koerner FC; Edgerton SM; Skates SJ; Yin S; McKenzie SJ; Panicali DL; Marks PJ; Fingert HJ
Cancer Res; 1989 Dec; 49(24 Pt 1):7147-52. PubMed ID: 2573426
[TBL] [Abstract][Full Text] [Related]
20. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.
Spyratos F; Ferrero-Poüs M; Trassard M; Hacène K; Phillips E; Tubiana-Hulin M; Le Doussal V
Cancer; 2002 Apr; 94(8):2151-9. PubMed ID: 12001111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
